Press Releases Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Market Closed - OTC Markets Other stock markets 02:34:32 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8058 ^USD	+2.65%		+0.60%	-32.85%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Mar. 13	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates	Apr. 16	AQ
Eloxx Pharmaceuticals : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases	Mar. 13	PU
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update	Nov. 13	AQ
Eloxx Pharmaceuticals : October 2023 Investor Presentation	23-10-10	PU
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction	23-10-10	AQ
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria	23-10-09	AQ
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	23-09-19	AQ
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	23-09-18	AQ
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013	23-09-07	AQ
Eloxx Pharmaceuticals : Management Change - Form 8-K	23-08-29	PU
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	23-08-15	AQ
Eloxx Pharmaceuticals : August 2023 Investor Presentation	23-08-14	PU
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update	23-08-14	AQ
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	23-08-14	AQ
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement	23-08-03	AQ
Eloxx Pharmaceuticals : July 2023 Investor Presentation	23-07-17	PU
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit	23-07-10	AQ
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study	23-06-29	AQ
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02	23-06-28	AQ
ELOXX PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-06-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Press Releases

Filters